Ampio rises on FDA ruling on Zertane questionnaire
Ampio rises on FDA decision that will allow studies of premature ejaculation drug to proceed
NEW YORK (AP) -- Shares of Ampio Pharmaceuticals Inc. rose Monday after the company said it is ready to conduct a new clinical trial of its premature ejaculation treatment Zertane.
Ampio said the Food and Drug Administration has questionnaire to be used in pivotal trial of Zertane. The study will measure the duration of sex and the patients' responses to the questionnaire.
Ampio shares rose 36 cents, or 9 percent, to $4.35 in midday trading.
Zertane is Ampio's most advanced drug, and it is also developing a version that combines Zertane with a treatment for impotence. The company is also studying an eye drug called Optina, an inflammation drug called Ampion, and Vasaloc, which treats kidney damage caused by diabetes.
